Alliance Pharma, a global leader providing bioanalytical, DMPK, and CMC testing services in the pharmaceutical and biopharmaceutical industry, and Drug Development Solutions, Ltd. (acquired in 2022), today announced…
Resolian, a global bioanalytical contract research organization (CRO) specializing in drug metabolism and pharmacokinetics for small and large molecules, has acquired Denali Medpharma…
As a CRO, meeting client expectations can be an ongoing challenge. What can organizations do to make sure their research is as effective and efficient as possible?
The area under the concentration vs. time curve is a useful description of exposure of drug following administration. There are different ways in which AUC may be calculated…
An understanding of the characteristics of drug exposure following administration and how it relates to safety and efficacy is critical for progressing drug development (e.g. in decision making for drug candidates…
This paper highlights oligonucleotides (OGNTs) as a revolutionary new class of drugs in personalized medicine due to their targeted approach to genetic diseases.
Copyright © 2024 Resolian Inc. All rights reserved.